LITERATURE REVIEW: PARKINSON’S DISEASE

Authors

  • Nishonov Shohidbek Yusufjonovich Dean of the Faculty of Medicine, Alfraganus University, Ph.D. in Medical Sciences, Associate Professor

DOI:

https://doi.org/10.55640/

Keywords:

Parkinson’s disease; neurodegeneration; α-synuclein; Lewy bodies; dopaminergic neurons; basal ganglia; motor symptoms; non-motor symptoms; deep brain stimulation; neuroprotection.

Abstract

Parkinson’s disease is a progressive neurodegenerative disorder characterized by the loss of dopaminergic neurons in the substantia nigra and the accumulation of α-synuclein aggregates known as Lewy bodies. Clinically, the disease presents with cardinal motor symptoms such as resting tremor, bradykinesia, and rigidity, while a wide range of non-motor manifestations—including cognitive impairment, autonomic dysfunction, sleep disturbances, and mood disorders—often precede motor onset. Modern therapeutic strategies are primarily symptomatic and aim to restore dopaminergic transmission through pharmacological treatments or deep brain stimulation. Despite significant advances, no current therapy effectively halts or reverses neurodegeneration. Ongoing research focuses on biomarkers, genetic mechanisms, immunotherapies targeting α-synuclein, and neuroprotective approaches to modify disease progression.

Downloads

Download data is not yet available.

References

1.Bloem, B. R., Okun, M. S., & Klein, C. (2021). Parkinson’s disease. The Lancet, 397(10291), 2284–2303.

2.Poewe, W., Seppi, K., Tanner, C. M., Halliday, G. M., Brundin, P., Volkmann, J., ... & Lang, A. E. (2017). Parkinson disease. Nature Reviews Disease Primers, 3, 17013.

3.Kalia, L. V., & Lang, A. E. (2015). Parkinson’s disease. The Lancet, 386(9996), 896–912.

4.Braak, H., Del Tredici, K., Rüb, U., de Vos, R. A., Jansen Steur, E. N., & Braak, E. (2003). Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiology of Aging, 24(2), 197–211.

5.Schapira, A. H. V., Chaudhuri, K. R., & Jenner, P. (2017). Non-motor features of Parkinson disease. Nature Reviews Neuroscience, 18, 435–450.

6.Travagli, R. A., & Ferrarese, C. (2022). Pathophysiology of Parkinson’s disease. Cellular and Molecular Neurobiology, 42(4), 775–797.

7.Obeso, J. A., Stamelou, M., Goetz, C. G., Poewe, W., Lang, A. E., Weintraub, D., ... & Schapira, A. H. (2017). Past, present, and future of Parkinson’s disease: A special essay on the 200th Anniversary of the Shaking Palsy.

Movement Disorders, 32(9)

8.Deuschl, G., Schade-Brittinger, C., Krack, P., et al. (2006).

A randomized trial of deep-brain stimulation for Parkinson’s disease. New England Journal of Medicine, 355(9), 896–908.

9.Armstrong, M. J., & Okun, M. S. (2020).

Diagnosis and treatment of Parkinson disease. JAMA, 323(6), 548–560.

Surmeier, D. J., Obeso, J. A., & Halliday, G. M. (2017).

10. Selective neuronal vulnerability in Parkinson disease. Nature Reviews Neuroscience, 18(2), 101–113.

Downloads

Published

2026-02-27

How to Cite

LITERATURE REVIEW: PARKINSON’S DISEASE. (2026). Journal of Multidisciplinary Sciences and Innovations, 5(02), 2374-2377. https://doi.org/10.55640/

Similar Articles

1-10 of 476

You may also start an advanced similarity search for this article.